Have a feature idea you'd love to see implemented? Let us know!

ATOS Atossa Therapeutics Inc

Price (delayed)

$0.9637

Market cap

$121.23M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.22

Enterprise value

$46.36M

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and ...

Highlights
The net income has grown by 10% YoY but it has contracted by 3.9% from the previous quarter
The company's EPS rose by 8% YoY but it fell by 4.8% QoQ
The quick ratio has dropped by 53% year-on-year and by 8% since the previous quarter
The company's equity fell by 25% YoY and by 8% QoQ

Key stats

What are the main financial stats of ATOS
Market
Shares outstanding
125.8M
Market cap
$121.23M
Enterprise value
$46.36M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.64
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
Gross profit
$0
Net income
-$26.91M
EBIT
-$26.91M
EBITDA
-$26.88M
Free cash flow
-$19.57M
Per share
EPS
-$0.22
EPS diluted
-$0.22
Free cash flow per share
-$0.16
Book value per share
$0.59
Revenue per share
$0
TBVPS
$0.63
Balance sheet
Total assets
$79.48M
Total liabilities
$5.8M
Debt
$0
Equity
$73.68M
Working capital
$71.32M
Liquidity
Debt to equity
0
Current ratio
13.3
Quick ratio
12.92
Net debt/EBITDA
2.79
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-30.5%
Return on equity
-32.6%
Return on invested capital
-3,105.7%
Return on capital employed
-36.5%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ATOS stock price

How has the Atossa Therapeutics stock price performed over time
Intraday
-1.66%
1 week
-13.96%
1 month
-19.69%
1 year
32.38%
YTD
9.51%
QTD
-36.6%

Financial performance

How have Atossa Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$29.49M
Net income
-$26.91M
Gross margin
N/A
Net margin
N/A
The net income has grown by 10% YoY but it has contracted by 3.9% from the previous quarter
The operating income rose by 3.5% QoQ and by 3.3% YoY

Growth

What is Atossa Therapeutics's growth rate over time

Valuation

What is Atossa Therapeutics stock price valuation
P/E
N/A
P/B
1.64
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS rose by 8% YoY but it fell by 4.8% QoQ
The company's equity fell by 25% YoY and by 8% QoQ
ATOS's P/B is 22% below its last 4 quarters average of 2.1 and 14% below its 5-year quarterly average of 1.9

Efficiency

How efficient is Atossa Therapeutics business performance
ATOS's return on invested capital has dropped by 163% since the previous quarter
The return on equity has declined by 19% year-on-year and by 12% since the previous quarter
The ROA has decreased by 15% YoY and by 11% from the previous quarter

Dividends

What is ATOS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ATOS.

Financial health

How did Atossa Therapeutics financials performed over time
Atossa Therapeutics's total liabilities has surged by 68% YoY
Atossa Therapeutics's current ratio has plunged by 53% YoY and by 7% from the previous quarter
ATOS's debt is 100% smaller than its equity
The company's equity fell by 25% YoY and by 8% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.